Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation

IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Chujie Li , Yonger Chen , Xin Yuan , Lian He , Xiaojun Li , Song Huang , Shaozhen Hou , Jian Liang
{"title":"Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation","authors":"Chujie Li ,&nbsp;Yonger Chen ,&nbsp;Xin Yuan ,&nbsp;Lian He ,&nbsp;Xiaojun Li ,&nbsp;Song Huang ,&nbsp;Shaozhen Hou ,&nbsp;Jian Liang","doi":"10.1016/j.ejphar.2020.173264","DOIUrl":null,"url":null,"abstract":"<div><p><span>Evidences showed that chronic stress (CS) can aggravate the situation of nonalcoholic fatty liver disease (NAFLD). </span>Vitexin<span> is one of the major components in hawthorn<span>, which is widely used to reduce blood lipid. This study was aimed to explore the therapeutic effects and potential mechanisms of vitexin on chronic stress mice with high-fat diet (CSHFD). The results showed that 5-week vitexin administration (40 mg/kg, i.g.) could obviously reduce hepatic fat deposition, alleviate lipid metabolism, and inhibit liver inflammation in CSHFD mice. In addition, vitexin significantly reduced hepatic macrophage infiltration, obviously down-regulated the mRNA and protein expressions<span><span> of hepatic SREBP-1c, FAS, ACC. Moreover, we also found that vitexin treatment could significantly inhibit the expressions of TLR4/NF-κB signaling in CSHFD mice. This results suggested that vitexin could ameliorate chronic stress combined with high-fat diet induced NAFLD, and its mechanisms is closely related to inhibit TLR4/NF-κB signaling and reduce fatty acid </span>synthesis proteins.</span></span></span></p></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"882 ","pages":"Article 173264"},"PeriodicalIF":4.2000,"publicationDate":"2020-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejphar.2020.173264","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299920303563","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 14

Abstract

Evidences showed that chronic stress (CS) can aggravate the situation of nonalcoholic fatty liver disease (NAFLD). Vitexin is one of the major components in hawthorn, which is widely used to reduce blood lipid. This study was aimed to explore the therapeutic effects and potential mechanisms of vitexin on chronic stress mice with high-fat diet (CSHFD). The results showed that 5-week vitexin administration (40 mg/kg, i.g.) could obviously reduce hepatic fat deposition, alleviate lipid metabolism, and inhibit liver inflammation in CSHFD mice. In addition, vitexin significantly reduced hepatic macrophage infiltration, obviously down-regulated the mRNA and protein expressions of hepatic SREBP-1c, FAS, ACC. Moreover, we also found that vitexin treatment could significantly inhibit the expressions of TLR4/NF-κB signaling in CSHFD mice. This results suggested that vitexin could ameliorate chronic stress combined with high-fat diet induced NAFLD, and its mechanisms is closely related to inhibit TLR4/NF-κB signaling and reduce fatty acid synthesis proteins.

Abstract Image

牡荆素通过抑制炎症改善高脂肪饮食引起的非酒精性脂肪肝的慢性应激
有证据表明慢性应激可加重非酒精性脂肪性肝病(NAFLD)的病情。牡荆素是山楂的主要成分之一,被广泛用于降血脂。本研究旨在探讨牡荆素对高脂饮食慢性应激小鼠(CSHFD)的治疗作用及其可能机制。结果表明,紫荆素给药5周(40 mg/kg, ig)可明显减少CSHFD小鼠肝脏脂肪沉积,减轻脂质代谢,抑制肝脏炎症反应。此外,牡荆素显著降低肝巨噬细胞浸润,明显下调肝脏SREBP-1c、FAS、ACC mRNA和蛋白表达。此外,我们还发现牡荆素处理可以显著抑制CSHFD小鼠TLR4/NF-κB信号的表达。上述结果提示牡荆素可改善慢性应激联合高脂饮食诱导的NAFLD,其机制与抑制TLR4/NF-κB信号通路、减少脂肪酸合成蛋白密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信